Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Summary

The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.

Timeline

Start

2008-12-15

Primary completion

2013-11-05

Completion

2014-10-27

Publications

• Results Campbell P, Thomas CM. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. J Oncol Pharm Pract. 2017 Mar;23(2):143-147. doi: 10.1177/1078155216634178. Epub 2016 Jun 23.

Drugs

Indications